

**CARDIOVASCULAR DRUGS:
STATINS AND LIPID LOWERING AGENTS**

	INSTIs		NNRTIs		PIs
	<ul style="list-style-type: none"> • BICTEGRAVIR (<i>Biktarvy</i>) • DOLUTEGRAVIR (<i>Tivicay, Triumeq, Juluca, Dovato</i>) • RALTEGRAVIR (<i>Isentress</i>) 	<ul style="list-style-type: none"> • ELVITEGRAVIR/ COBICISTAT (<i>Stribild, Genvoya</i>) 	<ul style="list-style-type: none"> • DORAVIRINE (<i>Pifeltro, Delstrigo</i>) • RILPIVIRINE (<i>Edurant, Complera, Odefsey, Juluca</i>) 	<ul style="list-style-type: none"> • EFAVIRENZ (<i>Sustiva, Atripla</i>) • ETRAVIRINE (<i>Intelence</i>) • NEVIRAPINE (<i>Viramune</i>) 	Boosted with ritonavir (Norvir) or cobicistat <ul style="list-style-type: none"> • ATAZANAVIR (<i>Reyataz, Evotaz</i>) • DARUNAVIR (<i>Prezista, Prezcobix, Symtuza</i>) • LOPINAVIR (<i>Kaletra</i>)

STATINS

<ul style="list-style-type: none"> • Atorvastatin (<i>Lipitor</i>) 		Potential for ↑ statin		Potential for ↓ statin	Potential for ↑ statin. Use lowest statin dose possible (maximum 20 mg atorvastatin daily).
<ul style="list-style-type: none"> • Rosuvastatin (<i>Crestor</i>) 		Potential for ↑ statin			Potential for ↑ statin. Use lowest statin dose possible (maximum 10 mg rosuvastatin daily).
<ul style="list-style-type: none"> • Pitavastatin (<i>Livalo</i>) 					
<ul style="list-style-type: none"> • Pravastatin (<i>Pravachol</i>) 		Potential for ↑ statin			Potential for ↑ statin
<ul style="list-style-type: none"> • Lovastatin (<i>Mevacor</i>), simvastatin (<i>Zocor</i>) 		Potential for ↑ statin and toxicity		Potential for ↓ statin	Potential for ↑ statin and toxicity

CARDIOVASCULAR

	INSTIs		NNRTIs		PIs
	<ul style="list-style-type: none"> • BICTEGRAVIR (<i>Biktarvy</i>) • DOLUTEGRAVIR (<i>Tivicay, Triumeq, Juluca</i>) • RALTEGRAVIR (<i>Isentress</i>) 	<ul style="list-style-type: none"> • ELVITEGRAVIR/COBICISTAT (<i>Stribild, Genvoya</i>) 	<ul style="list-style-type: none"> • DORAVIRINE (<i>Pifeltro, Delstrigo</i>) • RILPIVIRINE (<i>Edurant, Complera, Odefsey, Juluca</i>) 	<ul style="list-style-type: none"> • EFAVIRENZ (<i>Sustiva, Atripla</i>) • ETRAVIRINE (<i>Intencele</i>) • NEVIRAPINE (<i>Viramune</i>) 	Boosted with ritonavir (<i>Norvir</i>) or cobicistat <ul style="list-style-type: none"> • ATAZANAVIR (<i>Reyataz, Evotaz</i>) • DARUNAVIR (<i>Prezista, Prezcofix, Symtuza</i>) • LOPINAVIR (<i>Kaletra</i>)

FIBRATES

- Fenofibrate, bezafibrate, gemfibrozil

CHOLESTEROL ABSORPTION INHIBITOR

- Ezetimibe (*Ezetrol*)

GASTROINTESTINAL LIPASE INHIBITOR

- Orlistat (*Xenical*)

Potential for ↓ ARV absorption

BILE ACID SEQUESTRANTS

- Cholestyramine (*Olestry*), colestipol (*Colestid*)

Potential for ↓ ARV absorption

Mechanism of Drug Interactions, Management and Monitoring

	Mechanism of Interaction	Main Interacting ARVs	Management	Monitoring
Hmg-Coa Reductase Inhibitors (Statins)				
Lovastatin, simvastatin	Inhibition of CYP3A4	Ritonavir and cobicistat-boosted protease inhibitors and elvitegravir	Contraindicated. Use alternate statin.	Statin toxicity: myalgia, rhabdomyolysis
Atorvastatin, rosuvastatin, pravastatin	Inhibition of CYP3A4, OATP1B1, BCRP	Ritonavir and cobicistat-boosted protease inhibitors and elvitegravir	Use lowest statin dose possible and titrate to effect	Statin toxicity: myalgia, rhabdomyolysis
Pitavastatin	Primarily cleared via UGT, OATP1B1	None	Most ARVs may be used	Statin toxicity: myalgia, rhabdomyolysis
Orlistat	Reduced absorption of ARVs by decreasing dietary fat absorption	All antiretrovirals, particularly lipophilic agents	Take ARVs at least 2 hours before/after orlistat	Antiretroviral efficacy
Bile acid sequestrants	Reduced absorption of ARVs	All antiretrovirals	Take ARVs either 1 hour before or 4-6 hours after bile acid sequestrants	Antiretroviral efficacy

Legend:



No dose adjustment required.



Use combination with caution. Adjustment in drug dose or frequency or additional/more frequent monitoring may be required. May wish to consult with a pharmacist knowledgeable in HIV drug interactions.



Contraindicated/avoid combination.

A MANAGEMENT TOOL FOR **HIV** DRUG-DRUG INTERACTIONS

Printed with the assistance of an unrestricted educational grant from:



abbvie



GILEAD



MERCK



© 2019 Canadian HIV and Viral Hepatitis Pharmacists Network (CHAP) All listed brands are trademarks or registered trademarks of their respective owners.

